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ABSTRACT
Background: Vaccination programs reduce the
morbidity and mortality of diphtheria,
pertussis, and tetanus. Erythema nodosum is a
reactive erythema that can be associated with
infections, drugs, and many conditions. The
new onset of erythema nodosum after receiving
vaccination is uncommon.
Purpose: Combined reduced-antigen content
tetanus, diphtheria, and acellular pertussis
(Tdap) vaccine-associated erythema nodosum
is described and the reports of vaccine-related
erythema nodosum are summarized.
Methods: The clinical features of a 39-year-old
woman who developed erythema nodosum
after receiving Tdap vaccine are reported.
Using the PubMed database, an extensive
literature search was performed on erythema
nodosum, vaccine, and vaccination.
Results: Tdap, the most commonly used booster
vaccine against tetanus, diphtheria, and pertussis,
is well tolerated in all age groups. Local injection-
site reactionsare themostcommonadverseevents,
whereas headache, fatigue, gastrointestinal
symptoms, and fever are the most frequent
systemic events. Erythema nodosum has not
previously been reported in patients who have
received Tdap vaccine. The patient developed
erythema nodosum within 48 h after receiving
Tdap vaccine; her symptoms cleared and nearly all
skin lesions resolved within 2 weeks after initiating
oral treatment with ibuprofen, fexofenadine, and
prednisone. Vaccine-associated erythema
nodosum has previously been reported following
vaccination for cholera, hepatitis B, human
papillomavirus, malaria, rabies, small pox,
tuberculosis, and typhoid.
Conclusion: Vaccine-associated erythema
nodosum is uncommon. Erythema nodosum
occurring after Tdap vaccination is a rare, yet
potential, adverse effect.
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INTRODUCTION
The combined reduced-antigen content
tetanus, diphtheria, and acellular pertussis
(Tdap) vaccine is a single-dose booster vaccine
that not only maintains the standard of care for
tetanus and diphtheria protection but also
reduces pertussis morbidity [1–7]. Erythema
nodosum is a reactive erythema that can be
associated with infections, drugs, and many
conditions [8–12]; however, the new onset of
erythema nodosum after receiving a vaccine is
rare. A young woman who developed erythema
nodosum after receiving Tdap vaccine is
reported and vaccinations that have been
associated with erythema nodosum have been
summarized.
CASE REPORT
A healthy 39-year-old Japanese woman visited
her primary care physician for an annual
examination. She had received all of her
childhood vaccinations without any
complications. She did not have any history of
preceding infections, sore throat or diarrhea.
She also had no prior or current skin or systemic
diseases and her laboratory studies were normal.
There was no personal or family history of
tuberculosis. Her physician recommended
prophylactic vaccination with combined
tetanus-diphtheria-pertussis (Tdap) vaccine
since her booster immunization was due.
Informed consent was obtained from the
patient for being included in the study and for
the publishing of photographs. This article does
not contain any studies with human subjects
performed by the author.
Within 24 h of receiving Tdap vaccine, she
noted several areas of pruritus and swelling on
her distal lower extremities. During the next
24 h these areas enlarged and developed into
tender red nodules. The painful nodules
persisted and she sought dermatologic medical
attention.
Cutaneous examination, 7 days after
receiving Tdap vaccine, revealed tender
erythematous nodules on her legs (Fig. 1).
There was a large, 12 by 8 cm, erythematous
nodule on distal pretibial left leg (Fig. 1).
Multiple, individual and grouped, nodules
were present on her right leg; they were
located on the distal lateral thigh (4.0 by
2.5 cm), the proximal lateral calf (6.0 by
3.5 cm), the distal lateral calf (2.0 by 2.0 cm),
and the distal lateral leg proximal to the ankle
(each of 3 lesions measuring 2.5 by 2.5 cm)
(Fig. 2).
Correlation of her medical history, clinical
symptoms, and lesion morphology were
compatible with a diagnosis of Tdap vaccine-
Fig. 1 Distant (a) and closer (b) frontal views of the
anterior lower extremities of a 39-year-old Japanese woman
with erythema nodosum developing after she received
vaccination with Tdap vaccine. Tender, erythematous,
individual (left leg) and grouped (right leg), nodules are
present on the distal pretibial legs (a). Erythema nodosum
appears as a large, 12 by 8 cm, nodule on the distal pretibial
left leg (b)
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related erythema nodosum; however, the
differential diagnosis also included an Arthus-
like phenomenon induced by immunization
and erythema nodosum secondary to another
etiology with immunization being associated
by chance. Several circumstances favored
Tdap vaccine-related erythema nodosum.
Specifically, she had not receiving any topical
or systemic medications. Also, she had no
recent streptococcal pharyngitis or systemic
conditions such as Crohn’s disease,
sarcoidosis, or tuberculosis. Therefore, the
temporal association between her recent Tdap
vaccination and the development of the skin
lesion suggested that the development of her
erythema nodosum was related to her receiving
Tdap vaccine.
Symptomatic treatment was initiated: oral
ibuprofen 600 mg four times daily. Since a drug-
induced etiology was suspected, daily oral
systemic therapy with an antihistamine and a
corticosteroid was started: 180 mg of
fexofenadine and prednisone (60 mg for
4 days, followed by 40 mg for 3 days, and
followed by 20 mg for 2 days). Her symptoms
began to improve and the nodules started to
flatten within 3 days.
Follow-up examination occurred 2 weeks
after her initial visit. Her symptoms had
completely resolved. One of the nodules
proximal to her right ankle was smaller, yet
palpable with mild erythema of the skin. All of
her other nodules had completely flattened and
there was macular hyperpigmentation at the
sites.
DISCUSSION
The morbidity and mortality from the bacterial
diseases diphtheria, pertussis and, tetanus have
been dramatically reduced secondary to
vaccination programs beginning in infancy
[1–7]. The originally developed infant
combined diphtheria-tetanus-whole-cell
pertussis (DTwP) vaccine was subsequently
supplanted by the infant combined diphtheria-
tetanus-acellular pertussis (DTaP) vaccine that is
less reactogenic [1, 2]. Booster vaccination of
adolescents and adults is still necessary since
immunity—either vaccine induced or naturally
acquired—to pertussis is not lifelong. However,
because of the risk of increased reactogenicity
with successive doses, the infant DTaP vaccine is
not suitable for use as a booster vaccine in
adolescents and adults [1, 2].
The most commonly used booster vaccine
against tetanus, diphtheria, and pertussis in
adolescents and adults is the three-component
pertussis Tdap (BoostrixTM, GlaxoSmithKline,
Research Triangle Park, NC, USA) vaccine that
contains an aluminum adjuvant [1, 2]. The
Fig. 2 Distant (a) and closer (b) view of the woman’s
right leg show multiple individual and grouped nodules of
Tdap vaccination-associated erythema nodosum. Lesions
of erythema nodosum on the right leg are located on the
distal lateral thigh, the proximal lateral calf, the distal
lateral calf, and the distal lateral leg proximal to the ankle
(a). A group of 3 nodules of erythema nodosum are noted
on the distal right leg (b)
Dermatol Ther (Heidelb) (2013) 3:191–197 193
123
quantities of antigens (toxoids) in Tdap vaccine
are reduced by 10–50 percent of those in the
infantile DTaP vaccine. The three pertussis
antigen components are filamentous
haemagglutinin, pertactin, and pertussis toxin
[1, 2].
Combined reduced-antigen content tetanus,
diphtheria, and acellular pertussis vaccine is
well tolerated in all age groups [1–7]. The most
common adverse events associated with Tdap
vaccine administration are local injection-site
reactions such as pain, redness, swelling, and
increased upper-arm circumference [1–7].
Headache, fatigue, gastrointestinal symptoms
and fever are the most frequent systemic events
[1–7]. These adverse events occur in up to
approximately 20 percent of individuals, are
only mild or moderate in intensity, and are
typically transient [1–7].
Serious adverse events following Tdap
immunization are rare [5]. They include
allergic reactions (such as anaphylaxis), cardiac
conditions (pericarditis, myocardial infarction,
and arrhythmia), exacerbation of pre-existing
illnesses, general systemic symptoms,
infections, injection site cellulitis, neurologic
conditions (Guillain–Barre syndrome, Bell’s
palsy, seizure, demyelinating diseases,
and encephalopathy), syncope, and
thrombocytopenia [5]. However, to the best of
my knowledge, erythema nodosum has not
previously been described following
vaccination with Tdap.
Erythema nodosum is clinically
characterized by acute onset of painful, warm,
red subcutaneous nodules—of 1 to 5 cm in
diameter–appearing bilaterally on the pretibial
legs. Associated systemic symptoms may
include fever, fatigue, malaise, and arthralgias.
Microscopic examination of a lesion typically
demonstrates a septal panniculitis, with a
neutrophilic infiltrate; vasculitis is absent.
Within a few days to 2 weeks, the
erythematous nodules begin to slowly involute
by flattening and developing purple color that
subsequently evolves into a bruise-like macular
hyperpigmentation that has been referred to as
erythema contusiformis [8–12].
Erythema nodosum is most commonly
observed in young women—particularly those
between 20 and 50 years of age [8–12]. Indeed,
erythema nodosum occurs 4–6 times as often in
women as compared to men [8–12]. Although
the extensor leg below the knee is the most
frequent location, lesions may also appear on
other sites such as the thighs and extensor arms
[8–12].
Erythema nodosum can present as an
idiopathic reactive erythema. However, there
is an extensive list of infections (such as
bacterial, viral, fungal, mycobacterial, and
protozoan), drugs (such as antibiotics and oral
contraceptives), and conditions (such as
inflammatory bowel disease, pregnancy, and
sarcoidosis) that have been described in patients
with developed erythema nodosum. Some of
the erythema nodosum-associated etiologies
(such as streptococcal throat infection, oral
contraceptives and pregnancy, sulfonamides,
Crohn’s disease, and sarcoidosis) are more
commonly observed whereas other erythema
nodosum-related causes have only been noted
in a small number of patients or single
individuals [8–12].
Erythema nodosum has occurred following
vaccination; however, vaccines are an
uncommon etiology for this reactive erythema
(Table 1) [13–24]. To the best of my knowledge,
the currently described woman is the first
individual in whom erythema nodosum has
been reported following vaccination with Tdap.
Her symptoms and lesions began within 48 h
after she was vaccinated; she had no conditions
that have previously been noted to cause
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erythema nodosum and she was not taking any
medication that has previously been associated
with the development of erythema nodosum.
The lesion-associated tenderness and the
nodules both began to resolved within 3 days
after initiating oral treatment with a
corticosteroid and a long-acting antihistamine
daily, and a nonsteroidal anti-inflammatory
agent four times each day. During the next 1
weeks, her symptoms resolved and all but one
of the nodules had completely cleared.
The onset of clinical symptoms and skin
lesions is variable in patients with vaccine-
associated erythema nodosum. Similar to the








Tetanus, diphtheria, and pertussisg Current report
Typhoid and cholerah [24]
a Bacille–Calmette–Guerin (BCG) vaccine, a live attenuated vaccine derived from attenuated strains of Mycobacterium
bovis, is used to prevent tuberculosis [13]. A retrospective study of etiologic factors associated with erythema nodosum in
children was performed; BCG vaccination was the related etiology in 1 of 45 patients [14]. Another patient developed
erythema nodosum 30 days after BCG vaccination; the local inﬂammatory reaction caused by the vaccine was normal [15]
b Erythema nodosum has been associated with administration of hepatitis B vaccine prepared either from human serum
(Heptavax B, Merck & Co., Inc., Whitehouse Station, NJ, USA) [18] or by recombinant-DNA techniques (Engerix B,
GlaxoSmithKline, Research Triangle Park, NC, USA [16] and Recombivax HB, Merck & Co., Inc., Whitehouse Station,
NJ, USA [17])
c A 16-year-old girl developed erythema nodosum after administration of vaccine against human papillomavirus types 6, 11,
16, and 18 (Gardasil, Merck & Co., Inc., Whitehouse Station, NJ, USA) [19]
d Two of 10 volunteers (a 25-year-old Asian woman and a 26-year-old Caucasian woman—both taking oral contraceptives)
developed dermatology consultant-conﬁrmed erythema nodosum after receiving 1 dose of 20 lg Pvs25/ISA 51 vaccine
[a vaccine consisting of recombinant Pvs25 (a surface protein of mosquito stage of the malaria parasite Plasmodium vivax)
which is formulated with Montanide ISA 51 (a water-in-oil emulsion)] [20]
e An 11-year-old girl developed erythema nodosum at the site of a dog bite after receiving a vaccination against rabies [22].
Another patient, 35-year-old woman developed biopsy-conﬁrmed erythema nodosum a few days after receiving the second
dose of a rabies vaccine treatment: Rabipur (Novartis Vaccines and Diagnostics, Cambridge, MA, USA), a puriﬁed chick
embryo/second generation tissue culture vaccine [21]
f Three patients are reported who developed cutaneous eruptions that were essentially varioliform, but ranged from
erythema multiforme and erythema nodosum to severe hemorrhagic exanthems, on the 14th, 20th, and 22nd day after
primary vaccination [23]
g A 39-year-old woman developed erythema nodosum within 48 h after receiving a dose of the combined reduced-antigen
content tetanus, diphtheria, and acellular pertussis (Tdap) vaccine [current report]
h A 56-year-old woman developed pain and stiffness in both ankles, knees and lower back 24 h after receiving 0.5 ml of
typhoid vaccine (to prevent salmonella infection) and 1.0 ml of cholera vaccine (to prevent cholera infection)
intramuscularly; the symptoms were followed by the development of classical erythema nodosum on the anterior aspects of
both lower legs [24]
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rapid onset of Tdap-related erythema nodosum
within 48 h, symptoms and skin lesions of
erythema nodosum associated with hepatitis B
vaccine (prepared by recombinant-DNA
techniques) appeared within less than 24 h
[16] or after only 4 days [7], in the patients
who received either Engerix B
(GlaxoSmithKline, Research Triangle Park, NC,
USA) [16] or Recombivax (Merck & Co., Inc.,
Whitehouse Station, NJ, USA) [17]. In addition,
the woman who had previously received a
course of typhoid and cholera vaccine more
than 5 years earlier, developed symptoms 24 h
after her booster vaccination followed by classic
appearing erythema nodosum lesions on her
anterior lower legs [24]; similar to this patient,
erythema nodosum developed within a few
days after the second dose of rabies vaccine
[21] and 15 days after the second injection
of human papillomavirus vaccine (and
subsequently 10 days after the third injection
of Gardiasil 4 months later) [19]. In contrast,
vaccine-related erythema nodosum appeared
18, 14–22, and 30 days after vaccination with
malaria [20], small pox [23], or Bacille–
Calmette–Guerin [15], respectively.
The pathogenesis of vaccine-related
erythema nodosum remains to be established.
Many of the investigators favor the
development of erythema nodosum being
secondary to the antigen of the infectious
disease. However, it is impossible to absolutely
exclude the possibility of a hypersensitivity
reaction to one or more of the adjuvant
components used to prepare the vaccine.
CONCLUSION
The new onset of erythema nodosum after
receiving vaccination is uncommon, but has
been reported following vaccination for
cholera, hepatitis B, human papillomavirus,
malaria, rabies, small pox, tuberculosis, and
typhoid [13–24]. This is the first report of
erythema nodosum occurring after Tdap
vaccination for the prevention of tetanus,
diphtheria, and pertussis. It is important for
clinicians to be aware of this rare, yet potential,
adverse effect to Tdap vaccine.
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